logo-loader
AIM:SCLP OTC:SCNLF

Scancell Holdings PLC

Receive alerts
Market:
AIM
Price
10.25 GBX
Day Change
-
Market Cap:
£95.1 m
52 weeks high
20.99
52 weeks low
7.59

In brief

Scancell Holdings PLC is a clinical stage biopharmaceutical company that is leveraging its proprietary research, built up over many years of studying the human adaptive immune system, to generate truly novel medicines to treat significant unmet needs in cancer and infectious disease.

Adaptive immune responses include antibodies and T cells (CD4 and CD8), both of which can recognise damaged or infected cells.

In order to destroy such cancerous or infected cells, Scancell uses either vaccines to induce immune responses or monoclonal antibodies to redirect immune cells or drugs.

Snapshot

  • Scancell Holdings appoints new head of development
  • Scancell: US investment bank resumes coverage with punchy price target
  • Scancell CEO hails "exciting" high response rate to melanoma treatment